• Microbot Medical reported Q1 net loss widened to $3.67 million from $2.6 million year-ago as revenue turned to $105,000 from no revenue.
• Cost of revenues was $103,000, while research and development expense narrowed to $1.29 million from $1.46 million.
• Sales, general and administrative expense climbed to $3.03 million from $1.56 million, while financing income increased to $649,000 from $104,000.
• Working capital was about $73.1 million at March 31, 2026, down from about $76.4 million at Dec. 31, 2025.
• LIBERTY Endovascular Robotic System limited market release continued through quarter-end, with full market release starting in April 2026; CE Mark approval anticipated in second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Microbot Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-022792), on May 13, 2026, and is solely responsible for the information contained therein.